Healthy Clinical Trial
Official title:
Estimation of Interleukin-21 Levels in Gingival Crevicular Fluid in Patients With Periodontal Health and Disease Following Non-surgical Periodontal Therapy: A Clinico-biochemical Study
Human IL-21 is present in gingival crevicular fluid in periodontal health, gingivitis and chronic periodontitis. A significant increase in the concentration of IL-21 in gingival crevicular fluid is observed with an increase in the amount of periodontal destruction. Non- surgical periodontal therapy aided in decrease of GCF IL-21 levels in clinical gingivitis and chronic periodontitis
Introduction
Periodontal disease is a poly-microbial disease that affects tooth-supporting tissues.
Integral part of periodontal disease involves destruction of periodontal tissues that results
from stimulation of the bacterial challenge to host immune-inflammatory response. Chronic
periodontitis is the most common form of periodontal disease in adult population. The
bacterial plaque biofilm is the primitive factor for periodontitis, but the majority of
destruction of the periodontal tissues would eventually conclude from a sequence of
immune-inflammatory reactions. As a result of cellular activation, inflammatory mediators
include cytokines, chemokines etc. collectively contribute to tissue destruction and bone
resorption. Cytokines can be grouped as Th1, Th2, Th17 and T regulatory (Treg) based on their
expression pattern and effects on target cells or tissues.5 Classically, periodontal disease
has been explained by Th1/Th2 pathway. Th1 cells are more frequently detected in the early
stage of periodontal lesions suggesting that Th1 cells are associated with a protective
response against bacterial infection whereas Th2 cells predominate in the later and advanced
period of the disease, having a role in the destruction and progression of periodontal
lesions. Alternative type of host response to pathogenic bacteria has been described by the
IL-23/IL-17 pathway. This alternative pathway occurs when bacteria induce synthesis of
IL-23/17 rather than IL-12, which plays a pivotal role in initiation and maintenance of
inflammatory response. IL-23/17 pathway as compared to classical Th1/Th2 pathway is a much
fine tuned cellular immune response that has a multitude of functions that bridges the innate
and adaptive arm of the immune response.9 Th17 cytokines (IL-17, IL-21, IL-22, IL-6, Tumor
necrosis factor {TNF}-a, etc.)8 participate in periodontal disease, but whether their
dominant role is host-protective or destructive is questionable. These cytokines have not
been elucidated at different inflammatory status in periodontitis.
IL-21 is a type-I cytokine, structurally it appears similar to IL-2, IL-4, and IL-15
proteins. IL-21 is principally composed by activated T cells, but it directs a vast spectrum
of myeloid and lymphoid cells of the immune system, which facilitate IL-21 to modulate the
acquired and innate immunity.10 IL-21 compete in the immunity against tumor cells11 and
chronic viral infections,12 however, enormous accomplishment of IL-21 has been correlated
with the advancement of immune inflammatory diseases in various organs.13 IL-21 is heighten
in dermatological conditions like skin biopsies14 of patients with systemic lupus
erythematosus, psoriasis, and atopic dermatitis. In addition, IL-21 interpretation correspond
with the presence of Th17 cells in synovial fluid and peripheral blood of rheumatoid
arthritis patients.
Role of IL-21 in inflammation has been extensively studied; the treatment aspect on its
levels in periodontal diseases needs to be further explored. Therefore, in the light of the
above findings, the investigators determine the levels of interleukin-21 (IL-21) in GCF from
chronic gingivitis, chronic periodontitis and control patients before and after non-surgical
periodontal therapy along with the co-relation of clinical parameters of periodontal tissues
destruction.
MATERIAL AND METHODS:
PATIENTS:
Thirty four patients (19 males and 15 females, aged 20-60 years) were consecutively enrolled
over a six month period (April 2014 to September 2014) from the outpatient department of
periodontology, Krishnadevaraya College of Dental Sciences, Bangalore, and Karnataka. Ethical
clearance for the study was obtained from the institutional ethical committee
(02-D012-36773). The study was conducted in accordance with the ethical principles described
in the Declaration of Helsinki 2008. Procedure of the study was explained and informed
written consent was obtained from all the participants before their inclusion in the study.
Among them, 24 patients having diseased periodontium were grouped into 12 chronic gingivitis
and 12 chronic periodontitis patients whereas 10 healthy individuals were included as
control. Inclusion criteria were: patients having more than or equal to 14 functional teeth,
systemically healthy patients who had not received any form of surgical and non surgical
periodontal therapy or received antibiotics or non-steroidal anti-inflammatory therapy within
the past 6 months of the study. Chronic gingivitis was defined as having probing depth (PD)
less than or equal to 4mm and more than to 25% sites with gingival bleeding present (BOP).15
Chronic periodontitis was defined as having probing depth more than or equal to 5mm, RAL more
than or equal to 8mm, with more than or equal to 10% sites with BOP positive and evidence of
bone loss determined radiographically.16 Patients who volunteered with no evidence of
periodontal disease determined by the absence of increased PD or AL were considered as
healthy control group.
Clinical Measurements:
Clinical parameters were measured and evaluated for all the teeth excluding 3rd molars, at
all the six sites for each tooth (mesio-buccal, disto-buccal, disto-lingual, mid-lingual and
mesiolingual). These parameters consisted of pocket depth (PD), assessment of gingival
bleeding i.e gingival index (GI), dichotomous measurement of supragingival plaque
accumulation i.e plaque index (PI), and bleeding on probing (BOP) to the base of the crevice.
One calibrated examiner (MN) performed all the patient evaluations and measurements.
GCF samples collection and analysis:
In all three groups, GCF samples were collected at baseline and 6 weeks post treatment. Site
selection was based on the highest score recorded for single site in the oral cavity. A
single site in each subject that showed worst inflammatory manifestations (chronic
gingivitis) and the highest RAL level (chronic periodontitis) was selected for gingival
crevicular fluid collection. In our study, we selected a single site in each subject to avoid
pooling of samples from multiple sites, as periodontitis is a site specific disease. Prior to
the collection of GCF samples supragingival plaque was removed with cotton pellets avoiding
contact with marginal gingiva. Standard paperstrips were carefully inserted to a depth of
approximately 2mm, into the sulcus/pocket for 30 seconds for collection of GCF. Blood
contaminated strips were discarded and alternative site was used to obtain replacement
samples. In chronic gingivitis patients, alternative sample wre collected with the next
highest GI scores and in chronic periodontitis patients the next deepest Probing pocket depth
{PPD} was selected for the alternative sample site. A calibrated appliance was used to
quantify the GCF sample volume and reading were converted to actual volume (μL) by reference
to a standard curve, prepared using the periotron reading of volume of fluid (μL) distilled
water in perio-col strips. A blank gingival fluid collection (perio-col) strip was placed
between the periotron fluid meta sensors and the instrument was adjusted to display a reading
of zero. A microlitre syringe was used to accurately deliver 0.25-1.25 μL fluid (distilled
water) to perio-col strip. The strips were immediately placed between the periotron sensors.
The periotron score volume displayed the known volume of fluid recorded. This step was
repeated three more time with 0.25 μL of test fluid and the average score recorded. The above
step was repeated using volume of 0.5, 0.75, 1.0, 1.25 μL, and in every instance the mean
periotron value calculated and recorded. Once all the score were obtained, a standard curve
was computed with known fluid volume (X-axis) and periotron score (Y-axis). In a similar way
GCF volumes (from health, chronic gingivitis, chronic periodontitis) from study patients were
obtained automatically with periotron score. The interpolation from standard calibration
graph gave volume of fluid. After measurement of volume, the strips from the selected sites
were placed immediately into individual microcentrifuge tubes containing 200 μL of phosphate
buffer solution. The samples were stored at -80 °C until further analysis.
ELISA
The levels of IL-21 in the GCF were determined using ELISA according to the manufactures
instruction. To elute the proteins, the tube containing the periopaper strips were vortexed
and homogenized for 30 seconds and then centrifuged at 12,500 rpm at 4°C for 5 minutes. The
kit used monoclonal antibody MT 21.3 biotin and human recombinant IL-21 standard (captured
antibody). Samples were run in triplicate to authenticate the sensitivity of ELISA and all
the samples were found to be within the detection limit of ELISA. An ELISA reader (spectramax
190 Ab sorbance microplate reader; molecular devices; Sunnyvale, CA, USA) with 450 nm as
elementary wavelength was used to measure the absorbance of the substrate. Conversion of the
absorbance readings obtained, into definite volume (pg/mL) were performed using standard
reference curve. The protein concentration at each site (pg/mL) were determined by dividing
the total amount of IL-21 (pg) by gingival crevicular fluid volume (μL) and subsequently the
(pg/μL) values were converted into (pg/mL).
Periodontal treatment protocols:
At baseline, clinical parameters and collection of GCF samples for all patients was done. All
patients received a thorough oral hygiene instructions, a full mouth supragingival
subgingival scaling along with root planing. Non-surgical periodontal therapy for group III
was performed in 2-3 appointments. A single calibrated examiner (MN) provided treatment to
all study patients.
STATISTICAL ANALYSIS:
The power of study and sample size calculation was determined on the basis of change in GCF
IL-21 level. Current estimates as a pilot study which included 12 patients in each test group
and 10 in control group with total sample size of 34 patients. Type II error level of β =
0.20 (80% power) and type I error level of α=0.05 (5% probability) was calculated. The
distribution of the samples with respective values of PI, GI, BOP, PD, RAL and IL-21 levels
of pre-operatively and post-operatively was analyzed statistically. Data was entered in
Microsoft excel and analysed using SPSS {statistical package for social science}, ver.10.05)
package. Proportions were compared using Chi-square test (χ2) test of significance. Normality
of data was tested using Shapiro-Wilk test. A student t-test was performed to determine pre
and post treatment difference values. One way analysis of variance (ANOVA) was used to test
the difference between the groups. Comparison of the biochemical and clinical parameters were
performed using Kruskal-Wallis non-parametric test. P<0.05 was considered statistically
significant.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |